3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
31
Neoplasms
8
Endometrial Neoplasms
6
Neoplasm Metastasis
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Meningioma
3
Glioblastoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Retinoblastoma
1
Recurrence
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasm, Residual
1
Multiple Myeloma
1
Interventions
blinatumomab
9
Cyclophosphamide
7
Rituximab
6
Lenalidomide
6
Dexamethasone
5
Azacitidine
5
venetoclax
4
fludarabine
4
Cytarabine
4
fludarabine phosphate
3
Maintenance
3
Busulfan
3
tislelizumab
2
thymoglobulin
2
pembrolizumab
2
obinutuzumab
2
daratumumab
2
Whole-Body Irradiation
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Methotrexate
2
Melphalan
2
Immunotherapy
2
Imatinib Mesylate
2
Drug Therapy
2
Docetaxel
2
Decitabine
2
Clofarabine
2
Cladribine
2
Carboplatin
2
Calcium Dobesilate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm, Residual
×
abemaciclib
×
Clear all
NCT05708235
2026-03-05
MiRaDoR
MedSIR
Phase 2
Recruiting
976 enrolled